Mutations at HIV-1 reverse transcriptase (RT) codon 184 such as M184V confer resistance to two nucleos(t)ide RT inhibitors (NRTI), lamivudine (3TC) and emtricitabine (FTC). The prevalence of mutations at HIV-1 RT codon 184 was evaluated using three independent RT sequence databases from treatment-experienced (TE) and treatment-naïve (TN) individuals. Data were collected retrospectively from three centers: one in Italy and two in France between 1997 and 2016. In order to highlight the role of these mutations in conferring drug resistance, structural and thermodynamic analyses were conducted by means of computational approaches. Among 32,440 RT sequences isolated from TE and 12,365 isolated from TN patients, the prevalence of HIV-1 RT codon 184 substitutions in each group was 31.21% and 0.72%, respectively. The mutations M184L and M184T have been observed only in TE patients. In all cases but four, M184L and M184T mutations were present during NRTI treatment. Molecular recognition studies on M184L and M184T structures showed both FTC and 3TC thermodynamic profiles unfavorable in comparison with the wild-type sequence, corroborated by molecular dynamic simulations (MDS). In this study, we highlighted two new resistance mutations in vivo for NRTI resistance.
| INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) therapies targeting the reverse transcriptase (RT) are the most prescribed drugs to treat HIV infection. [1] However, the use of these treatments can be limited due to the rapid emergence of drug-resistant viral mutants. [2] Therefore, providing an exhaustive list of NRTI resistance mutations is crucial for guiding clinicians.
Investigating mutations occurring at the methionine 184 residue, located in the RT polymerase active site, is highly clinically relevant. Indeed, they are the most frequent mutations involved in treatment failure [3, 4] and, among the single mutations, they are able to confer the highest NRTI resistance (up to 100-fold increase). [5, 6] The International Antiviral Society (IAS) Drug Resistance Mutations, the World Health Organization, [7] and the French ANRS (National Agency for AIDS Research) AC 11 Resistance Group all reported two NRTI resistance mutations at this codon: M184V (ATG>GTG) and M184I (ATG>ATA). It is well established that both substitutions confer a high-level resistance to lamivudine (3TC) and emtricitabine (FTC) [5, 8] and can also cause cross-resistance to abacavir (ABC) and didanosine (ddI). [9] [10] [11] The molecular mechanisms involved in the link between the emergence of these mutations and NRTI treatment have been widely investigated. M184V and M184I variants displayed a reduced incorporation of oxathiolane-cytosine nucleotides, [5, 6, [12] [13] [14] [15] probably due to steric hindrance. Compared to the wild type (WT), M184V mutation confers a reduced fitness, [16] [17] [18] [19] which may explain that the HIV-1 reverts to wild type when NRTI treatment ceases. [20] It has also been shown that this variant increases fidelity of HIV-1 RT, [16, [21] [22] [23] [24] [25] [26] thus reducing genetic diversification, one of key natural defensive mechanisms. M184I is considered as a transient variant since it appears early under 3TC-based regimens and then disappears in favor of M184V mutant due to its lower fitness. [23, [26] [27] [28] [29] [30] It has been observed that both variants increase or restore susceptibility to other NRTI, such as zidovudine (AZT), tenofovir (TDF), or stavudine (d4T); [6, 16, 31] therefore, these mutations do not contraindicate continuation of 3TC or FTC therapy if combined to other NRTI drugs.
In vitro analyses revealed other potential NRTI resistance substitutions at this site, such as M184A, M184L, [21, 32] , and M184T, [23, 26] whereas they have never been investigated in vivo to date. M184L and M184T mutations have been reported by the Stanford University HIV-1 drug resistance database, [33] but (a) difference of M184L mutation frequencies between untreated and treated isolates does not reach statistical significance, and (b) for M184T mutation, the association with non NRTI therapies could not be excluded; therefore, those mutations have not been retained as NRTI resistance mutations.
Analyzing three databases of RT sequences derived from drug resistance testing of two centers in France and one center in Italy in treatment-naïve and treatment-experienced patients, we found two rare mutations in HIV-1 RT codon 184, M184L and M184T. The aim of this study was to explore these two rare mutations that have not been considered as resistance mutations despite experimental data. For this purpose, we explored patients' genotypes and treatment histories and we used a molecular modeling approach aimed at exploring M184 variants' affinity profile in the presence of the main NRTI drugs.
| METHODS AND MATERIALS

| Database
The data were retrospectively collected from three large independent RT sequence databases: two in France (Bichat and Pitié Salpêtrière Hospital, Paris) and one in Italy (University of Rome Tor Vergata, Rome) from 1997 to 2016 (from 2008 and 2016 for the Pitié Salpêtrière database due to missing clinical information). The prevalence of mutations at HIV-1 RT codon 184 was assessed in both treatment-naïve (TN, n = 12,365) and treatment-experienced individuals (TE, n = 32,440). Additionally, the link between mutations and drug resistance was explored by analyzing genotypes and treatment histories.
| Structural and docking analyses
To explore the role of M184T and M184L mutations, we used the X-ray crystallographic coordinates of RT complexed to DNA deposited in the Protein Data Bank [34] with the code 4R5P. [35] The heterocyclic moiety of the n + 1th nucleotide in the template overhang was modified according to the base complementary with respect to the incoming NRTI. From this starting model, the mutants (M184I, M184T, and M184L) were generated by single-residue replacement in both chains and energy minimized using OPLS_2005 [36] as force field and the GB/SA water implicit solvation model [37] as implemented in macromodel ver. 11.0. a Docking simulations were performed by using SP protocol [38] of glide ver. 6.9 b in the following conditions: 100 generated conformations, a grid box centered onto the co-crystallized inhibitor, and the all default settings. In order to evaluate the predicted binding mode of the drugs in the mutated enzyme, the Boltzmannweighted Glide energies were useful to select the best poses and the Emodel score was evaluated for the further analysis. we calculated the ΔEmodel, expressed in kcal/mol, between the WT sequence and the mutants. Then, for WT and mutated complexes, we started from the best docking pose to perform 100 ns of MDS by using desmond ver. 3.8. The complexes were solvated in an orthorhombic box with a buffer of 10 Å TIP3P (transferable intermolecular potential 3-point) water, and the counter ions were added to neutralize the system net charge. After a previous optimization step of the solvated model, we relaxed the system with Martyna-Tobias_Klein isobaric-isothermal ensemble (MTK_NPT). This preliminary stage included two minimization simulations of 2,000 steps: In the first run, the complex was restrained with a force constant of 50 kcal (mol A) −1 , while in the second one, all the system was released without any restraint. Afterward, a first simulation with the NVT ensemble was carried out at 10K; meanwhile, the three successive simulations were performed using the NPT ensemble, a temperature of 300 K, and a pressure of 1 bar with the Berendsen thermostatbarostat. In order to elucidate the behavior of 3TC and FTC, during all trajectories, the root mean square deviation (RMSD) of the ligand and the protein was calculated on all atoms and on the backbone atoms, respectively. Moreover, the simulation interaction diagram and the simulation event analysis were used to evaluate the structural insights and the energetic profile of the drugs within the WT enzyme and mutated structures during the whole simulations.
All 3D figures were obtained with pymol graphics and modeling package ver. 1.7.6 (The pymol Molecular Graphics System, Ver 1.7.6 Schrödinger, LLC). All calculations were performed on a Linux cluster with 336 dual-Xeon processor nodes.
| RESULTS
| Prevalence of mutations at codon 184 on RT gene
Among 32,440 RT sequences from TE and among 12,365 from TN patients, the prevalence of HIV-1 RT codon 184 substitutions (n = 10,214) in each group was 31.21% (n = 10,125) and 0.72% (n = 89), respectively.
As expected, among the 10,214 mutations at position 184, the most commonly occurring mutation was M184V irrespective of exposure to therapy (TE patients: 90.91%, n = 9205; TN patients: 95.51%, n = 85). The less common substitution M184I was also found in both groups (11.31%, n = 1,145 in TE and 5.62%, n = 5 in TN patients).
As expected, we found rare mutations only in TE patients: M184L (0.15%, n = 15) and M184T (0.11%, n = 11). One of the 25 patients actually displayed multiple virus mutations at RT codon 184 including the two rare L and T variants (M/L/T/P/S). Note that while the M184T variant was found within homogenous viral population in almost 50% of cases, the M184L mutations were almost all found within an heterogeneous viral population including the more frequent M184V variant (see Table 1 ).
Finally, we also found in TE patients 2 M184C, 1 M184Y, and 1 M184R/M mutations.
| Virus characteristics
We specifically focused on the M184L and M184T mutations as they have been rarely explored and are the most frequent among rare 184 mutations.
Among viruses harboring M184L mutation (n = 15), 46.67% were subtype B (n = 7) and 20% subtype CRF02_ AG (n = 3). In viruses presenting M184T mutation, we found 72.73% of subtype B (n = 8) and 18.18% of subtype CRF02_ AG (n = 2) ( Table 1) .
When available (n=8), data on previous genotypes showed that all 184L variants resulted from a first A to G transition (corresponding to 184V variants) and a second G-to-C transversion (resulting in a L/V double population). By contrast, M184T mutation seemed to arise directly from the T-to-C transition (ATG to ACG), except for one patient for which we observed the alternative 184T codon ACA that requires two transitions.
| Drug history
As this retrospective study included data from patients with long history of treatment in different hospitals, sometimes in different countries, genotype at Day 0 (initiation of treatment) was not available. Thus, it was difficult to establish a strong causal link between drugs and emergence of M184L and M184T mutations. Nevertheless, we observed that in all cases but four (two of which were exempt from drugs the year before the sequencing), M184L and M184T mutations were present in viruses of patients receiving NRTI containing regimen at the time of genotypic test.
For M184L mutations, the most frequent antiretroviral drugs used at failure were 3TC and ABC (n = 7; 46.67%).
For M184T, 3TC was used in more than half of the patients at failure (n = 6; 54.54%); FTC, ddI, d4T, and TDF in three patients (27.27%).
| Docking and molecular dynamic simulations of NRTI against RT mutated complexes
Concerning TDF and ABC molecular recognition, for the analyzed mutants at position 184, we observed an increased binding affinity of both drugs in comparison with that in the presence of the wild type (WT) (TDF: ∆Emodel M184V = +3.71 kcal/mol; ∆Emodel M184T = +2.88 kcal/mol/ABC: ∆Emodel M184V = +15.91 kcal/mol; ∆Emodel M184T = +9.45 kcal/mol). By contrast, for the cytosine analogues, we noticed an opposing profile. Specifically, both FTC (ΔEmodel M184V = −6.17 kcal/ mol; ΔEmodel M184T = −11.78 kcal/mol) thermodynamic profile and 3TC thermodynamic profile (ΔEmodel M184V = −5.72 kcal/mol; ΔEmodel M184T = −9.23 kcal/mol) were remarkably unfavorable with respect to that of the WT. Regarding to the M184L mutated complex, after TDF (ΔEmodel M184L = +6.79 kcal/mol) and ABC (ΔEmodel M184L = +3.38 kcal/mol) docking analysis, we found that the drugs showed a favorable thermodynamic profile with respect to the WT model. By contrast, in M184L mutated complex, FTC and 3TC were both associated with a decreased binding affinity toward the enzyme (for FTC, ΔEmodel M184L = −5.70 kcal/mol; for 3TC, ΔEmodel M184L = −5.67 kcal/mol) with respect to the WT complex. In agreement with their energy profile in the presence of M184L substitution, 3TC and FTC revealed less stabilized configurations into the RT binding pocket due to a decreased number of contacts between the drugs and the mutated enzyme, if compared to the WT sequence. In particular, regarding RT M184L in complex with 3TC, we observed that the drug engaged one hydrogen bond with D113 and a π-π interaction with a DNA guanine nucleobase ( Figure 1b) ; meanwhile, in the RT WT complex, in addition to these, 3TC was involved in the π-cation interaction with R72 and the hydrogen bond with Y115 (Figure 1a) . In the RT M184L in complex with FTC, we noticed that the best binding pose was not oriented as in the WT, thus establishing three hydrogen bonds with K65 and D113 and one π-cation interaction with R72, but missing two π-π interactions with the above-mentioned guanine in the WT complex (Figure 2a,b) .
In the presence of M184T mutation, a smaller number of good contacts between both 3TC and FTC and the enzyme were found (Figures 1c and 2c) . In detail, two π-π interactions with the same DNA guanine and one π-cation interaction with R72 between FTC and the enzyme were observed, whereas the RT WT in complex with FTC showed also other two hydrogen bonds with D113 and Y115. Concerning the RT M184T in complex with 3TC, the drug engaged only two hydrogen bonds with R72 and K65.
As shown in Table 2 and Figure 3 , M184V/I mutations, analyzed as negative control in our validating procedure, were associated with a remarkably decreased global number of interactions, in agreement with their drug resistance profile. As regards all analyzed mutants, in the ABC molecular recognition versus the mutated enzyme, if compared to the WT, we found a quite similar profile in terms of good interactions. Meanwhile, as observed in 3TC and FTC complexes, in the presence of all mutations at position 184, a decreased number of good contacts were detected between TDF and the enzyme, with respect to WT interactions.
With the aim to investigate 3TC and FTC binding mode into the HIV-1 RT pocket during the time, we analyzed the structural stability and the contributions of hydrophobic, water bridges, π-π, and hydrogen-bonding interactions of both drugs in complex with the enzyme in the presence of M184L and M184T mutations. Regarding 3TC complex, we appreciated that, after the equilibration step of MDS, in the presence of M184L, the mutated complex was associated with a decreased stability trend with respect to that of the WT complex. Meanwhile, in the presence of M184T, the behavior of the mutated structure is quite similar to that of the WT. The average RMSD values of the HIV-1 RT backbone atoms of WT, M184L, and M184T mutants were 2.9, 3.5, and 3.0 Å, respectively. In the WT and M184L complexes, the drug remained stable during all the simulation. By contrast, for the M184T mutated complex, we observed that 3TC decreased its stability with respect to the WT trend. In the presence of FTC, our structural analysis revealed that WT and both the mutated complexes showed a Note. dCTP, dGTP, and dATP: cytosine, guanosine, and adenine triphosphate, respectively, represent the natural substrates in competition with each drug. The opposite trend ΔEmodel of the substrate in comparison with that of the drug is rational. *A negative value showed a disadvantageous energy profile of the mutant with respect to that of the WT. similar stability trend. The average RMSD values of the HIV-1 RT backbone atoms of WT, M184L, and M184T mutants were 2.8, 2.7, and 2.7 Å, respectively. However, we noticed that both 3TC and FTC, in the presence of mutations, were associated to a fluctuating behavior into the HIV-1 RT binding pocket, if compared to the WT structure. After the first 50 ns, for both studied mutations, we noticed that 3TC and FTC energetic profiles were unfavorable compared with that of the WT. In particular, in the WT complex, we found an increased number of hydrogen bonds between 3TC and K65, K70, R72, and Q219 residues, if compared to the mutated structures. Regarding FTC, in the WT complex, we observed that the drug engaged hydrogen bonds with K65, K70, R72, D113, A114, Y115, Q151, and K219 residues. Instead, in the presence of M184L and M184T mutants, FTC lose the pivotal hydrogen bonds with A114, Y115, Q151, K219, and K65, Y115 residues, respectively.
| DISCUSSION
It is now well established that M184V and M184I mutations occurring in the RT polymerase active site of HIV-1 reduced its susceptibility to 3TC/FTC drugs. Whereas other mutations, such as M184L, M184T, or M184A, have been described and studied in vitro, [17, 21, 23, 26] there is still a lack of data that allow considering these variants as NRTI-resistant mutants.
In a large cohort of HIV-1-infected patients, we observed that M184L and M184T mutations occurred under and/or after NRTI treatment. The rareness of these mutants is in line with previous data. [33] Docking simulation analyses seemed to confirm the reduced M184L and M184T mutants' affinity for the two NRTI 3TC and FTC, similar to the M184V variant.
Longitudinal genotypic data on M184L mutations (CTG) suggested that the methionine substitution arose from a first transition step, resulting in the more frequent M184V variant (GTG). That is supported by the frequency of L/V double populations in patients with M184L variant. Regarding the idea that transversions occur less frequently than transitions, [39] it is not surprising that M184V (GTG) preceded M184L mutation (CTG) in all patients except one as this mutation would require a transversion (A to C) if arising directly from the WT methionine codon (ATG). Similarly, it has been shown that M184I mutation transiently precedes M184V mutation and then disappears due to the outgrowth of the M184V mutant. [17, 23, [26] [27] [28] [29] [30] In vitro studies demonstrated that M184L variants had less fitness than the wild type, but also compared to M184I or V mutants. [21] The fact that M184L mutations were associated with lower levels of virus load in our study is in line with this observation. Moreover, Boyer et al. [21] suggested that the lower infectious ability of this variant compared to other nucleoside resistance mutations at 184 codon probably explained why this mutant has rarely been reported in vivo. Again, the rareness of M184L mutants found in our study sustains this hypothesis. Thus, how can we explain the emergence of M184L mutation? Only in one patient, we had access to multiple genotypes repeated on a long period. In this case, we observed that the M184L mutation disappeared, whereas M184V one persisted. Thus, we can postulate that M184L mutation confers a transitory advantage to HIV in some particular conditions (drug therapy, the coexistence of other mutants) and that this advantage is rapidly counterbalanced by a low fitness, leading to the disappearance of this variant. Interestingly, it has been suggested that M184V might have not greater fidelity, [40] which can explain why we observe the emergence of further resistance mutation such as M184L. Computational protocol revealed that M184L substitution conferred a disadvantaged energetic profile of FTC and 3TC drugs due to a remarkably reduced network of interactions with the mutated enzyme, if compared to the WT. To our knowledge, this is the first study to provide molecular insights on behalf of a role of M184L mutation in NRTI resistance.
M184T rareness in experienced patients is in line with its presumed lower fitness, as reflected by the reduced replication activity [41, 42] or the lower cell transmission efficacy previously observed for this mutation. [26] Contrary to what we reported for M184L, M184T mutation was detected mainly within a homogeneous viral population. Moreover, all patients harboring this mutation received 3TC and/or FTC at mutation sequencing (except two who were free of treatment 1 year before sequencing), with the majority of them (7/10) only NRTI drugs. Moreover, the absence of 184T variants in naïve-therapy patients would support the association/selection of these mutants under drug pressure. These observations are in accordance with both 3TC and FTC calculated reduced binding affinity toward M184T mutant revealed by our docking simulation analyses. Altogether, these results are in favor of the role of M184T in NRTI resistance. As evidenced by the structural analyses, we can hypothesize that similar to M184V and M184I variants, [5, 6, [12] [13] [14] [15] M184T and M184L would work as beta branches amino acid resulting in a reduced incorporation of oxathiolane-cytosine nucleotides and in a remarkable shift of the oxathiolane ring due to steric hindrance (Figures 1 and 2 ).
In conclusion, to our knowledge, this is the first in vivo study reporting M184L and M184T mutations. In vitro data have previously suggested that these variants might exist in vivo only in treatment-naïve patients due to their inferior fitness compared to M184V and M184I mutations. Our structural and thermodynamic analyses have allowed for the first time to further investigate the role of these mutations. Moreover, phenotype experiments in B and non-B subtypes should be conducted to better characterize the relevance of those mutations.
